These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8093026)

  • 1. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines.
    Igaki H; Sasaki H; Kishi T; Sakamoto H; Tachimori Y; Kato H; Watanabe H; Sugimura T; Terada M
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1090-5. PubMed ID: 8093026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
    Zheng J; Hou P; Zhou C
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV.
    Olshan AF; Weissler MC; Pei H; Conway K; Anderson S; Fried DB; Yarbrough WG
    Oncogene; 1997 Feb; 14(7):811-8. PubMed ID: 9047388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
    Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
    Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
    Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
    Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Deletion and down-regulation of mts1/p16 gene in human gastric cancer].
    Lu Y; Gao C; Cui J
    Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):189-91. PubMed ID: 9387251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
    Hirama T; Miller CW; Wilczynski SP; Koeffler HP
    Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
    Liu Q; Yan YX; McClure M; Nakagawa H; Fujimura F; Rustgi AK
    Oncogene; 1995 Feb; 10(3):619-22. PubMed ID: 7845688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
    Huang L; Lang D; Geradts J; Obara T; Klein-Szanto AJ; Lynch HT; Ruggeri BA
    Mol Carcinog; 1996 Feb; 15(2):85-95. PubMed ID: 8599583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
    Zariwala M; Xiong Y
    Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4.
    Schrump DS; Chen GA; Consuli U; Jin X; Roth JA
    Cancer Gene Ther; 1996; 3(6):357-64. PubMed ID: 8988838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer].
    Takamura H; Fushida S; Hashimoto T; Yagi M; Miyazaki I
    Nihon Rinsho; 1996 Apr; 54(4):1043-8. PubMed ID: 8920671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
    Srivenugopal KS; Ali-Osman F
    Oncogene; 1996 May; 12(9):2029-34. PubMed ID: 8649864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines.
    Kees UR; Ranford PR; Hatzis M
    Oncogene; 1996 May; 12(10):2235-9. PubMed ID: 8668350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
    He J; Allen JR; Collins VP; Allalunis-Turner MJ; Godbout R; Day RS; James CD
    Cancer Res; 1994 Nov; 54(22):5804-7. PubMed ID: 7954404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.